全CSL Behringサイト内検索

Saving Lives for More Than a Century

ZLB Behring and its parent company, CSL Limited, continue to build on a long legacy of innovation in patient care. ZLB Behring traces its beginnings to the 1904 founding of Behringwerke, a company established by the first winner of the Nobel Prize in Medicine, Emil von Behring. In 1916 our parent company, CSL Limited, was founded to supply vaccines to the people of Australia. During the 20th century, leading companies came together to ultimately form ZLB Behring. We have specialized in plasma therapies for more than 60 years to improve the quality of life for patients with hemophilia, immune deficiency disorders and inherited emphysema.   Emil von Behring, an innovator with serum therapies who won the first Nobel Prize in Physiology and Medicine
Our life-saving therapies are used in trauma and surgical care, and help prevent blood-related diseases in newborns. ZLB Behring, providing biotherapies for life for more than a century.
View an interactive timeline of CSL Behring's rich corporate history.
1901Emil von Behring wins first Nobel Prize in Medicine
German doctor Emil von Behring wins the first Nobel Prize in Physiology and Medicine for his work on serum therapies. Von Behring’s pioneering work results in the modern methods of immunization that have largely eradicated diphtheria worldwide.
1904Emil von Behring creates Behringwerke
Emil von Behring creates Behringwerke to produce sera and vaccines to combat infectious diseases.
1913Anti-infectious agents
Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
1940WWII: Largest supplier of albumin for U.S. military
Armour becomes the largest supplier of human albumin for the U.S. military during World War II.
1946Europe’s first human plasma fractionation
Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale.
1949ZLB established
ZLB is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland.
1951ZLB mandate to supply blood products
ZLB receives a mandate from the Swiss government to supply blood products through the Swiss Red Cross Blood Transfusion Service.
1954First pasteurized plasma protein solution
The Zentrallaboratorium Blutspendedienst (ZLB) makes the first pasteurized plasma protein solution.
1955Behringwerke researchers discover Alpha-1
Alpha1-antitrypsin, a proteinase inhibitor, is discovered, purified and characterized for the first time by researchers of Behringwerke.
1970Japan’s first IVIg
Launch of Gamma-Venin®, the first IVIg product in Japan.
1981World’s first pasteurized factor VIII therapy
Haemate® human plasma coagulation factor VIII/von Willebrand factor complex is first marketed in Europe for the treatment of patients with hemophilia A. It is the first pasteurized factor VIII product in the world.
1984First IVIg approved in U.S.
ZLB BTS Swiss Red Cross gets FDA approval for its natural, polyvalent immunoglobulin. This product is the first IVIg preparation to be approved in the United States.
1986Humate-P® approved in U.S.
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for the prevention and control of hemorrhagic episodes in patients with hemophilia A.
1988Japan’s first fibrin sealant
Launch of Beriplast® P, the first fibrin sealant in Japan.
1993Helixate® approved in U.S.
The FDA approves Helixate® recombinant coagulation factor VIII for the treatment of hemophilia A.
1998€50 million plant modernization
Centeon (the predecessor company of Aventis Behring) completes a major, 50 million euro capital project to modernize its production facilities in Marburg, Germany.
1999First von Willebrand factor in U.S.
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for treatment of von Willebrand disease, the most common hereditary bleeding disorder.
1999Marburg: State-of-the-art Ig facility
A state-of-the-art production building for immunoglobulins is built in Marburg, Germany.
2000New formulation of recombinant Factor VIII
Helixate® FS/ Helixate® NexGen recombinant coagulation factor VIII formulated with sucrose for the treatment of hemophilia A. Approved by FDA for use in U.S. and by EMEA for use in 15 countries.
2000ZLB Bioplasma established
CSL acquires ZLB Blood Transfusion Service of Swiss Red Cross to establish ZLB Bioplasma, headquartered in Bern.
2000Gettin’ in the Game
The company launches Gettin’ in the Game, local workshops that promote the value of exercise among children with bleeding disorders.
2001ZLB Plasma Services established
CSL acquires 47 plasma collection centers and laboratory facilities operated by Nabi Plasma Collection Centers (U.S.) and creates ZLB Plasma Services.
2001World’s largest plasma collection business
Aventis Behring acquires 42 plasma centers from Seralogicals, forming the world’s largest plasma collection business.
2001Foundation established
The company establishes a foundation for research and advancement of patient health—the only non-profit foundation dedicated exclusively to charitable, scientific and educational endeavors that benefit the bleeding disorders community.
2002Rhophylac® launched in Germany
Rhophylac® human anti-D immunoglobulin is launched in Germany.
2002Junior National Championships
The company launches Junior National Championships in partnership with the National Hemophilia Foundation to promote the value of exercise for children with bleeding disorders.
2003Carimune® NF launched in U.S.
The company begins marketing Carimune® NF human normal immunoglobulin for intravenous (IV) administration in the United States.
2003Zemaira® approved in U.S.
FDA approves Zemaira® human alpha1-proteinase inhibitor for individuals with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema.
2003Assurance Program launched
The Assurance Program is launched to ensure that people who rely on our recombinant and plasma-derived therapies can continue to receive these vital treatments even if they experience a lapse in third-party, private health insurance.
2004ZLB Behring established
CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring.
2004EMEA approves Mononine®
The EMEA approves Mononine® human coagulation factor IX concentrate for the treatment of hemophilia B patients undergoing surgery, exposed to trauma, or experiencing severe, spontaneous hemorrhage. The company becomes the first to market a factor IX product approved for this method of treating these indications.
2004Rhophylac® approved in U.S.
ZLB’s Rhophylac® human anti-D immunoglobulin is approved by the FDA.
2005Mix2Vial™ introduced
ZLB Behring introduces the Mix2Vial™ alternate transfer device, a new way to reconstitute products.
2006Groundbreaking: state-of-the-art Ig plant
Construction begins on a new immunoglobulin manufacturing plant at ZLB Behring’s Bern, Switzerland, facility.
2006Vivaglobin® approved in U.K.
Vivaglobin® licensed for use in the U.K. in adults and children who require antibody replacement due to primary immunodeficiency.
2006State-of-the-art plant licensed by FDA
Highly automated facility in Kankakee, Illinois to allow for increased production of Zemaira®.
2006Vivaglobin® first SCIg in U.S.
U.S. Food and Drug Administration (FDA) grants marketing approval for Vivaglobin® human normal immunoglobulin for subcutaneous administration. Vivaglobin is the first FDA-approved subcutaneous immunoglobulin (SCIg) treatment.
2006Humate-P® 50% volume reduction
Humate-P® human coagulation factor VIII/von Willebrand factor complex is now available featuring a smaller diluent—50 percent less in all assay sizes, shortening infusion time and requiring less storage space.

ZLB Behring continues to build on this legacy of innovation and patient care.